Factors related to distant metastasis and prognosis of nasopharyngeal carcinoma

doi:10.3760/cma.j.issn.1673-422X.2014.02.008

Abstract

Abstract: Distant metastasis is the main cause of treatment failure in nasopharyngeal carcinoma (NPC). Clinical relevant factors such as age, gender, tumor staging can affect the distant metastasis and prognosis of NPC. Molecular markers of NPC distant metastasis include EB virus DNA, p53, epidermal growth factor receptor and vascular endothelial growth factor, which are expected to become the biological indicators of NPC prognosis. In addition, the pathological classification and the treatment means are also the affecting factors for NPC prognosis.

Key words: Nasopharyngeal neoplasms, Neoplasm metastasis, Prognosis

Zhang Hanwen, Peng Xun. Factors related to distant metastasis and prognosis of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2014, 41(2): 103-106.

References

［1］ Sultan I, Casanova M, Ferrari A, et al. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study［J］. Pediatr Blood Cancer, 2010, 55(2): 279-284. ［2］ Han F, Zhao C, Huang SM, et al. Longterm outcomes and prognostic factors of reirradiation for locally recurrent nasopharyngeal carcinoma using intensitymodulated radiotherapy［J］. Clin Oncol (R Coll Radiol), 2012, 24(8): 569-576. ［3］ Jin Y, Cai XY, Cai YC, et al. To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area［J］. Eur J Cancer, 2012, 48(6): 882-888. ［4］ Xiao G, Cao Y, Qiu X, et al. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma［J］. BMC Cancer, 2013, 13(1): 226. ［5］ Lu X, Wang FL, Guo X, et al. Favorable prognosis of female patients with nasopharyngeal carcinoma［J］. Chin J Cancer, 2013, 32(5): 283-288. ［6］ Pan J, Tang T, Xu L, et al. Prognostic significance of expression of cyclooxygenase2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma［J］. Head Neck, 2013, 35(9): 1238-1247. ［7］ Liu F, Xiao JP, Xu GZ, et al. Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma［J］. Radiat Oncol, 2013, 8(1): 157. ［8］ Lai SZ, Li WF, Chen L, et al. How does intensitymodulated radiotherapy versus conventional twodimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?［J］. Int J Radiat Oncol Biol Phys, 2011, 80(3): 661-668. ［9］ Xu L, Pan J, Wu J, et al. Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break［J］. Radiother Oncol, 2010, 96(1): 94-99. ［10］ Mao YP, Li WF, Chen L, et al. A clinical verification of the Chinese 2008 staging system for nasopharyngeal carcinoma［J］. Ai Zheng, 2009, 28(10): 1022-1028. ［11］ Pan CC, Lu J, Yu JR, et al. Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: a study of 1027 cases and review of the literature［J］. Exp Ther Med, 2012, 4(2): 334-338. ［12］ Peng X, Chen S, Du C, et al. Clinical features and prognostic factors in patients with nasopharyngeal carcinoma relapse after primary treatment［J］. Head Neck Oncol, 2013, 5(2): 21. ［13］ Pan C, Wu P, Yu J, et al. CTguided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma［J］. Int J Hyperthermia, 2011, 27(6): 549-554. ［14］ Wang HY, Sun BY, Zhu ZH, et al. Eightsignature classifier for prediction of nasopharyngeal ［corrected］ carcinoma survival［J］. J Clin Oncol, 2011, 29(34): 4516-4525. ［15］ Cai MB, Han HQ, Bei JX, et al. Expression of human leukocyte antigen G is associated with prognosis in nasopharyngeal carcinoma［J］. Int J Biol Sci, 2012, 8(6): 891-900. ［16］ Xie X, Wang H, Jin H, et al. Expression of pAkt affects p53 codon 72 polymorphismbased prediction of response to radiotherapy in nasopharyngeal carcinoma［J］. Radiat Oncol, 2013, 8(1): 117. ［17］ Zhang R, Zhao Y, Zhang S, et al. The expressions of EphrinB2 and VEGF in nasopharyngeal carcinoma and their clinical significance［J］. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2013, 27(4): 178-180. ［18］ Chan KC, Hung EC, Woo JK, et al. Early detection of nasopharyngeal carcinoma by plasma EpsteinBarr virus DNA analysis in a surveillance program［J］. Cancer, 2013, 119(10): 1838-1844. ［19］ Chai SJ, Pua KC, Saleh A, et al. Clinical significance of plasma EpsteinBarr Virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma［J］. J Clin Virol, 2012, 55(1): 34-39. ［20］ Lai SZ, Li WF, Chen L, et al. How does intensitymodulated radiotherapy versus conventional twodimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?［J］. Int J Radiat Oncol Biol Phys, 2011, 80(3): 661-668. ［21］ Lin S, Pan J, Han L, et al. Nasopharyngeal carcinoma treated with reducedvolume intensitymodulated radiation therapy: report on the 3year outcome of a prospective series［J］. Int J Radiat Oncol Biol Phys, 2009, 75(4): 1071-1078. ［22］ Ouyang PY, Xie C, Mao YP, et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by metaanalysis of published literaturebased randomized, controlled trials［J］. Ann Oncol, 2013, 24(8): 2136-2146. ［23］ Ji X, Xie C, Hu D, et al. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma［J］. PLoS One, 2013, 8(2): e56208. ［24］ Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrentadjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma［J］. J Natl Cancer Inst, 2010, 102(15): 1188-1198. ［25］ Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial［J］. Lancet Oncol, 2012, 13(2): 163-171. ［26］ Liang ZG, Zhu XD, Zhou ZR, et al. Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a metaanalysis of 793 patients from 5 randomized controlled trials［J］. Asian Pac J Cancer Prev, 2012, 13(11): 5747-5752. ［27］ Ma BB, Kam MK, Leung SF, et al. A phase Ⅱ study of concurrent cetuximabcisplatin and intensitymodulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma［J］. Ann Oncol, 2012, 23(5): 1287-1292. ［28］ Chen CY, Zhao C, Gao L, et al. An openlabeled, multicentric clinical study of cetuximab combined with intensitymodulated radiotherapy (IMRT) plus concurrent chemotherapy in locoregionally advanced (LA) nasopharyngeal carcinoma (NPC): a 2year followup report［J］. J Clin Oncol, 2012, 30 Suppl: 5535. ［29］ Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multiinstitutional trial［J］. Lancet Oncol, 2012, 13(2): 172-180.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[4]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[7]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[8]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[9]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[10]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[11]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[12]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[13]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[14]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[15]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.